Posted innews Ophthalmology
Long-Term Safety and Ophthalmic Outcomes of Voretigene Neparvovec-rzyl in US Clinical Practice: Interim Multicenter Observational Findings
Interim real-world data over nearly 4 years confirms the long-term safety and sustained visual benefits of voretigene neparvovec-rzyl in treating inherited retinal dystrophies, with manageable procedure-related adverse events including chorioretinal atrophy.
